The FDA is scheduled to rule in October on the Plymouth Meeting biotechnology company’s application for what could become its first product in the market.
Read More from Bizjournals.com Feed (2025-02-17 17:26:56)
Inovio stock plummets 25% after FDA denies accelerated review for lead drug candidate
